The Week That Was in NorthAsia@Smartkarma
This is the second report of "The Week That Was in North Asia@Smartkarma". This is a collaborative report among Travis Lundy, Mio Kato, CFA,...
285 Views
The Week That Was in NorthAsia@Smartkarma - Jelly Drinks, Dental Implants, & Tires
This is the inaugural report of "The Week That Was in North Asia@Smartkarma. This is a collaborative report among Travis Lundy, Mio Kato, CFA,...
293 Views
Chugai Pharmaceutical-Exceptionally Productive In-House R&D Driving Strong Growth
We publish an in-depth analysis of Chugai Pharmaceutical arriving at a DCF derived fair value of ¥ 4,200. Chugai’s strategic alliance with its...
203 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
522 Views
ACE910 (Emicizumab) – A Novel Factor VIII (FVIII) –Mimetic Bi-Specific Antibody
ACE910 is yet another (first one being Rheumatoid Arthritis treatment Actemra) blockbuster potential late stage program that validates Chugai’s...
171 Views